Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
ibalizumab c-c chemokine receptor type 5 biotech NA drugbank HIV Seropositivity[MeSHID:D006679]
HIV Infections[MeSHID:D015658]
Communicable Diseases[MeSHID:D003141]
Blood[MeSHID:D001769]
Infection[MeSHID:D007239]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational antagonist
ibalizumab t-cell surface glycoprotein cd4 biotech NA drugbank , DGIDB HIV Seropositivity[MeSHID:D006679]
HIV Infections[MeSHID:D015658]
Communicable Diseases[MeSHID:D003141]
Blood[MeSHID:D001769]
Infection[MeSHID:D007239]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 21.22 approved,investigational antagonist,inhibitor
ibalizumab t-cell surface glycoprotein cd4 biotech NA drugbank , DGIDB HIV Seropositivity[MeSHID:D006679]
HIV Infections[MeSHID:D015658]
Communicable Diseases[MeSHID:D003141]
Blood[MeSHID:D001769]
Infection[MeSHID:D007239]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 21.22 approved,investigational antagonist
ibalizumab t-cell surface glycoprotein cd4 NA Successful target TTD NA NA approved unknown
ibalizumab t-cell surface glycoprotein cd4 biotech NA drugbank , DGIDB HIV Seropositivity[MeSHID:D006679]
HIV Infections[MeSHID:D015658]
Communicable Diseases[MeSHID:D003141]
Blood[MeSHID:D001769]
Infection[MeSHID:D007239]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 21.22 approved,investigational antagonist,antibody
ibalizumab c-x-c chemokine receptor type 4 biotech NA drugbank HIV Seropositivity[MeSHID:D006679]
HIV Infections[MeSHID:D015658]
Communicable Diseases[MeSHID:D003141]
Blood[MeSHID:D001769]
Infection[MeSHID:D007239]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational antagonist
click here to return to the previous page